Oral drug molnupiravir seen as 'key trump card' in Japan's b

The treatment developed by Merck could receive fast-track approval by the end of the year, and other oral drugs to fight the coronavirus are not far behind.

Related Keywords

Shimane , Japan , Switzerland , Yokohama , Kanagawa , Japanese , Swiss , Takeshi Urano , Isao Teshirogi , Ridgeback Biotherapeutics , Fumio Kishida , Ryuichi Kiyama , Shimane University Faculty Of Medicine , Shionogi Co , U Atea Pharmaceuticals , Chugai Pharmaceutical Co , Pfizer Inc , Drug Administration , Merck Co , Prime Minister Fumio Kishida , Shimane University , Atea Pharmaceuticals , Health , Merck , Drugmakers , Shionogi , Covid 19 , Ovid 19 In Japan , Medicine ,